Literature DB >> 24668768

Respiratory assessment in centronuclear myopathies.

Barbara K Smith1, Melissa Goddard, Martin K Childers.   

Abstract

The centronuclear myopathies (CNMs) are a group of inherited neuromuscular disorders classified as congenital myopathies. While several causative genes have been identified, some patients do not harbor any of the currently known mutations. These diverse disorders have common histological features, which include a high proportion of centrally nucleated muscle fibers, and clinical attributes of muscle weakness and respiratory insufficiency. Respiratory problems in CNMs may manifest initially during sleep, but daytime symptoms, ineffective airway clearance, and hypoventilation predominate as more severe respiratory muscle dysfunction evolves. Respiratory muscle capacity can be evaluated using a variety of clinical tests selected with consideration for the age and baseline motor function of the patient. Similar clinical tests of respiratory function can also be incorporated into preclinical CNM canine models to offer insight for clinical trials. Because respiratory problems account for significant morbidity in patients, routine assessments of respiratory muscle function are discussed.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  canine; genetics; muscle disease; myopathy; respiratory assessment

Mesh:

Year:  2014        PMID: 24668768      PMCID: PMC4140950          DOI: 10.1002/mus.24249

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  104 in total

Review 1.  Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement.

Authors:  Jonathan D Finder; David Birnkrant; John Carl; Harold J Farber; David Gozal; Susan T Iannaccone; Thomas Kovesi; Richard M Kravitz; Howard Panitch; Craig Schramm; Mary Schroth; Girish Sharma; Lisa Sievers; Jean M Silvestri; Laura Sterni
Journal:  Am J Respir Crit Care Med       Date:  2004-08-15       Impact factor: 21.405

2.  Respiratory function in congenital muscular dystrophy and limb girdle muscular dystrophy 2I.

Authors:  C Dohna-Schwake; R Ragette; U Mellies; V Straub; H Teschler; T Voit
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

3.  Life satisfaction of individuals with Duchenne muscular dystrophy using long-term mechanical ventilatory support.

Authors:  J R Bach; D I Campagnolo; S Hoeman
Journal:  Am J Phys Med Rehabil       Date:  1991-06       Impact factor: 2.159

4.  Pulmonary afferent control of breathing as end-expiratory lung volume decreases.

Authors:  J F Green; M P Kaufman
Journal:  J Appl Physiol (1985)       Date:  1990-05

5.  Maximal static respiratory pressures in generalized neuromuscular disease.

Authors:  L F Black; R E Hyatt
Journal:  Am Rev Respir Dis       Date:  1971-05

6.  Maximal static pressures in healthy children.

Authors:  C Gaultier; R Zinman
Journal:  Respir Physiol       Date:  1983-01

7.  Predicted normal values for maximal respiratory pressures in caucasian adults and children.

Authors:  S H Wilson; N T Cooke; R H Edwards; S G Spiro
Journal:  Thorax       Date:  1984-07       Impact factor: 9.139

8.  Evaluation of pulmonary function in neuromuscular disease.

Authors:  R C Griggs; K M Donohoe; M J Utell; D Goldblatt; R T Moxley
Journal:  Arch Neurol       Date:  1981-01

9.  Validation of a technique to assess maximal inspiratory pressure in poorly cooperative patients.

Authors:  J D Truwit; J J Marini
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

10.  Respiratory muscle decline in Duchenne muscular dystrophy.

Authors:  Sonia Khirani; Adriana Ramirez; Guillaume Aubertin; Michèle Boulé; Chrystelle Chemouny; Véronique Forin; Brigitte Fauroux
Journal:  Pediatr Pulmonol       Date:  2013-07-08
View more
  2 in total

Review 1.  Gene therapy in monogenic congenital myopathies.

Authors:  Xuan Guan; Melissa A Goddard; David L Mack; Martin K Childers
Journal:  Methods       Date:  2015-10-14       Impact factor: 3.608

2.  Diaphragm assessment in mice overexpressing phospholamban in slow-twitch type I muscle fibers.

Authors:  Val Andrew Fajardo; Ian Curtis Smith; Eric Bombardier; Paige J Chambers; Joe Quadrilatero; Allan Russell Tupling
Journal:  Brain Behav       Date:  2016-04-22       Impact factor: 2.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.